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Left Ventricular Systolic Performance Changes
in Mild Hypertensive Subjects Treated with
Antihypertensive Monotherapy or Placebo: The
Treatment of Mild Hypertension Study (TOMHS)
Should We Worry About the
Hypercholesterolemic Effects of
Anti-Hypertensive Medications?
Robert J. Bryg, David J. Bryg, Jon P. Schrage, Joseph P. Johns, William
F Graettinger. University ofNevada School ofMedicine and VAMC, Reno, NV
Several large studies have demonstrated improved morbidity and mortality
with lowering of blood pressure (BP) in hypertension IHTN). The drugs which
have been shown to lower BP and cardiovascular (CV) risk are beta blocking
agents and thiazide diuretics. In spite of the documented benefit from the
use of these agents, there is a tendency among some physicians to avoid
these two classes of drugs when treating HTN. One of the reasons quoted is
that both of these classes of drugs increase cholesterol levels, which is pos-
tulated to negate the CV risk reduction afforded by BP lowering. This study
was undertaken to determine the magnitude of benefit from the lowering
of BP with these drugs and compare it with the expected loss of benefit
due to increased cholesterol levels with these drugs. A decision analysis
was constructed utilizing a new life expectancy (LE) function. L1FESPANS
(Lagrange Interpolated Functions of Empirical Survival Percentages Approx-
imated by NEVADA Simulations) is designed to individualize mortality pre-
diction utilizing mortality data from the National Center for Health Statistics
and numerous large epidemiological studies. Modifiable factors which are
included in this model to assist in the survival prediction include: age, sex,
race, BR cholesterol level, current smoking history, and body mass index.
For the initial analysis, a 10% reduction in BP with a 5% increase in abso-
lute cholesterol level with these agents was assumed. Sensitivity analyses
were performed for a wide range of initial BPs, cholesterol levels and smok-
ing history. Reduction of BP with either of these agents resulted in 1-5 years
of additional LE depending on baseline conditions. Significant increases in
LE were predicted even in the elderly. A 5% rise in cholesterol, in contrast,
was associated with a 0.0-0.6 year decrease in LE. The reduction in LE for
increased cholesterol was at most 28% of the increase in LE due to BP lower-
ing. Women had a slightly greater reduction of LE from increased cholesterol
In conclusion, without taking the other metabolic effects of these agents into
consideration, the increase in CV risk due to the small predicted increase in
cholesterol only partially negates the benefits of BP lowering. These predic-
tions are based on studies utilizing high dose (50-100 mg) diuretics. Lower
doses will have even less effect on lipid profiles and the negative LE changes
in hypertensive patients.
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Glycogen Loading In Vivo Reverses Decreased
Function After Ischemic Preconditioning In Vitro
Population Prevalence of Wolff-Parkinson-White
Syndrome
1997-91 I
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Torsten Doens!, Patrick Guthrie, Heinrich Taegtmeyer. Uni~ of Texas Houston
Medical School, Houston, TX
We recently observed that glycogen loading of the heart in vivo improves
ischemia tolerance to the same extent as ischemic preconditioning (IP). We
have now tested the hypothesis that glycogen loading is beneficial in a pro-
tocol where IP per se is not effective. We perfused hearts from fed animals
with bicarbonate buffer containing glucose (10 mM). Five min IP with 5 min
preconditioning-reperfusion (IP515) or 10 min normoxic perfusion (Control,
C) were preceded by a 15 min stabilization period and followed by 15 min
global. no flow ischemia witl 30 min of reperfusion. Glycogen loaded hearts
came from fasted animals, were perfused with buffer containing glucose
(10 mM). lactate (10 mM) and insulin (10 mU/ml) and were subjected to the
same protocol as IP515. Cardiac power and heart rate were assessed contin-
uously. Postischemic recovery was assessed by postischemic power as %
of preischemic power. Hearts were freeze-clamped for metabolites. Results:
Glycogen levels in vivo were higher in the glycogen loaded hearts than in C
1140 ± 4.5 vs. 70 ± 6.6 I-'mollg dry). IP515 did not improve postischemic re-
covery compared to C (68.5 ± 3.7% vs. 71.4 ± 3.5% of preischemic power,
n ~ 9 each). However, glycogen loading of this group resulted in a full re-
turn of cardiac power post ischemia (101 ± 6.1 %, n ~ 8). Levels of glucose-
6-phosphate IG-6-P), pyruvate, and lactate were not different in IP5/5 and C
and returned to preischemic levels with reperfusion. Glycogen loaded hearts
maintained elevated G-6-P and lactate levels with reperfusion. Conclusions:
Glycogen loading improves ischemia tolerance where IP fails to do so. Thus,
glycogen or glycogen breakdown may playa crucial role in myocardial pro-
tection.
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Little is known about the epidemiology of Wolff-Parkinson-White (WPW) syn-
drome in the general population. Virtually all previous studies have been ei-
ther case series from tertiary care centers or limited to young adult males
screened for military training. To date, there are no detailed studies of the
prevalence of WPW in the general population. To determine the prevalence
of WPW in the general population, we used the Marshfield Epidemiologic
Study Area (MESA). a population laboratory of 50,000 people residing in 12
contiguous zip codes in central Wisconsin. Prevalence was determined as
of 7/1/91 among MESA residents who had a diagnosis of WPW between
1/1/79 and 6/30/91. Cases were identified by reviewing the medical records
and electrocardiograms of: a) all 32 MESA residents with the WPW diagno-
sis identified by International Classification of Diseases, 9th Revision (ICD-9)
Code 426.7 as a hospital discharge or outpatient clinic diagnosis, b) 600 pa-
tients with suspected supraventricular arrhythmias identified by three ICD 9
codes, and c) all patients who had an invasive electrophysiology study for
overt WPW syndrome in our institution over the last 10 years.
Results: We identified 25 prevalent cases of WPW resulting in an overall
population prevalence of 5.1/10,000 (95% C.I, 3.1-7.1).
Age specific-prevalence rates per 10,000 were: 0-19 years - 2.0; 20-39
years - 5.5; 40-59 years - 9.6; >60 years - 4.8. There was no significant
difference in males versus females. Al125 verified cases were identified from
the 32 potential cases with ICD-9 Code 426,7, indicating that this code is
100% sensitive and has a 78% positive predictive value for WPW syndrome.
Conclusions: 1) The prevalence of WPW in the general population is lower
than that reported in selected populations and appears to be highest in those
of late middle-age. 2) Based on the findings of our study, we estimate that
there are approximately 130,000 individuals in the United States with elec-
trocardiographic documentation of WPW.
Philip Liebson, Greg Grandits, Ronald Prineas, Sinda Dianwmba, Richard Grimm.
Rush Medical College, Chicago, IL; University of Minnesota, Minneapolis, MN
Few large scale studies have evaluated long term effects of antihypertensive
monotherapy (MT) versus placebo (P) on left ventricular (LVI systolic perfor-
mance. Over a period of 4 years, 844 subjects with mild hypertension (mean
BP: 140/911 without cardiac disease were treated with one of 5 MTs or R all
receiving nutritional-hygienic intervention. 2-D directed M-mode echocardio-
grams evaluated LV function at baseline, 3 months and annually through 4
years. Average changes over4 years were compared between combined MT
groups and P. Average decrease in BP was 15.9/12.3 mmHg in the MT group
and 9.1/8.6 mmHg in the Pgroup. Forglobal systolic performance, stroke vol-
ume, ejection fraction, and fractional shortening (FS) increased with MT but
decreased in P (p < 0.01 (MT vs PI. Average change from baseline in stroke
volume was -3.0% with P and +1.7% with MT. Cardiac output, stroke work
index and minute work index decreased similarly in both MT and P. Peak-
and end-systolic stress (ESS) increased significantly more in P than MT Ip
< 0.01). Total peripheral resistance decreased more in the MT group (p <
0.001). For indexes of contractility, ESS/ES volume index increased more in
the P group, FS/ESS increased in MT and decreased in Rand SBP/ES dimen-
sion decreased more in the MT group (p < 0.02 for eachl.
These findings suggest that even in mild hypertensives without underlying
LV dysfunction, the addition of MT to nutritional-hygienic therapy can pro-
duce small, though significant changes in LV performance characteristics.
Effect of Hormone Replacement Therapy on
Fibrinogen Level in Postmenopausal Women in
the Framingham Offspring StUdy
Murray A. Mittleman, Otavio C.E. Gebara, Patrice Sutherland, Travis Matheney,
Izabela Lipinska, Francine K. Welty, Daniel Levy, Peter W.F Wilson, James E. Muller,
Geoffrey H. Tofler. Institute for Prevention of Cardiovascular Disease, Deaconess
Hospital, Harvard Medical School, and Framingham Heart StUdy, Boston, MA
Hormone replacement therapy (HRT) is associated with a decreased risk of
coronary heart disease (CHD) in postmenopausal women, but the mecha-
nism of its protective effect is not fully characterized. To evaluate the relation-
